3American Diabetes Association.Standards of medical care in diabetes-2008[J].Diabetes Care,2008,31(Suppl 1):S12-S54.
4胡仁明 樊东升.糖尿病周围神经诊疗规范.中国糖尿病杂志,2009,17(10):721-723.
5Young MJ,Breddy JL,Veves A,et al.The prediction of diabetic neropathic foot ulceration using vibration perception thresholds.A prospective study[J].Diabetes Care,1994,17(6):557-560.
6Apelqvist J,Bakker K,van Houtum WH,et al.Practical guidelines on the management and prevention of the diabetic foot:based upon the International Consensus on the Diabetic Foot (2007) Prepared by the International Working Group on the Diabetic Foot[J].Diabetes Metab Res Rev,2008,24(Suppl 1):S181-S187.
7Shy ME,Frohman EM,So YT,et al.Quantitative sensory testing:report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology[J].Neurology,2003,60(6):898-904.
8Deshpande N,Metter EJ,Ling S,et al.Physiological correlates of age-related decline in vibrotactile sensitivity institution of origin[J].Neurobiol Aging,2008,29(5):765-773.
9Al-Wakeel JS,Hammad D,Al Suwaida A,et al.Microvascular and macrovascular complications in diabetic nephropathy patients referred to nephrology clinic[J].Saudi J Kidney Dis Transpl,2009,20(1):77-85.
10K(a)rvestedt L,Mrtensson E,Grill V,et al.Peripheral sensory neuropathy associates with micro-or macroangiopathy:results from a population-based study of type 2 diabetic patients in Sweden[J].Diabetes Care,2009,32(2):317-322.
